



Human Dengue Virus IgG antibody ELISA Kit

Enzyme Immunoassay for the determination of Dengue Virus IgG in serum and plasma

Catalog number: ARG80538

Package: 96 wells

For research use only. Not for use in diagnostic procedures.

TABLE OF CONTENTS

SECTION	Page
INTRODUCTION	3
PRINCIPLE OF THE ASSAY	4
MATERIALS PROVIDED & STORAGE INFORMATION.....	5
MATERIALS REQUIRED BUT NOT PROVIDED.....	5
TECHNICAL HINTS AND PRECAUTIONS	6
SAMPLE COLLECTION & STORAGE INFORMATION	7
REAGENT PREPARATION	7
ASSAY PROCEDURE	7
CALCULATION OF RESULTS.....	9
QUALITY ASSURANCE	11

MANUFACTURED BY:

Arigo Biolaboratories Corporation

Address: No. 22, Ln. 227, Gongyuan Rd., Hsinchu City 300, Taiwan

Phone: +886 (3) 562 1738

Fax: +886 (3) 561 3008

Email: info@arigobio.com

INTRODUCTION

Dengue virus is a single-stranded RNA virus of about 50 nm in diameter belonging to the genus Flavivirus. Dengue and dengue hemorrhagic fever are caused by one of four closely related, but antigenically distinct, virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). Infection with one of these serotypes does not provide cross protective immunity, so persons living in a dengue-endemic area can have four dengue infections during their lifetimes. The viruses are transmitted by *Aedes aegypti*, a domestic, day-biting mosquito that prefers to feed on humans. Infection with dengue viruses produces a spectrum of clinical illness ranging from a nonspecific viral syndrome to severe and fatal hemorrhagic disease. It is primarily a disease of the tropics; its global distribution is comparable to that of malaria, and an estimated 2.5 billion people live in areas at risk for epidemic transmission. - Globally, there are an estimated 50 to 100 million cases of dengue fever and several hundred thousand cases of dengue hemorrhagic fever.

- The case-fatality rate of DHF in most countries is about 5%; most fatal cases are among children and young adults.
- Important risk factors for DHF include the strain and serotype of the infecting virus, as well as the age, immune status, and
- Genetic predisposition of the patient.
- Risk groups: residents of or visitors to tropical urban areas.

Species	Disease	Symptoms	Mechanism of Infection
Dengue virus	Dengue Dengue hemorrhagic fever (DHF) or Breakbone fever	Sudden onset of fever, severe headache, myalgias and arthralgia leukopenia, thrombocytopenia and hemorrhagic manifestations	Transmission by mosquitos (<i>Aedes aegypti</i>)

Human Dengue Virus IgG antibody ELISA Kit ARG80538

The presence of virus resp. infection may be identified by

- Serology: Detection of antibodies by ELISA

Infection produces lifelong immunity, but the antigenically distinct serotypes do not provide cross-protective immunity, so a person can theoretically experience four dengue infections; a dengue vaccine is not available

PRINCIPLE OF THE ASSAY

This assay employs the qualitative enzyme immunoassay technique. Dengue Virus antigens has been pre-coated onto a microtiter plate. Standards or samples are pipetted into the wells and any Dengue virus antibody present is bound by the immobilized antigens. After washing away any unbound substances, an HRP-conjugated antibody specific for human IgG is added to each well and incubate. Following the washing of any unbound antibody-enzyme reagent, a substrate solution (TMB) is added to the wells and color develops in proportion to the amount of antigen-antibody binding in the initial step. The color development is stopped by the addition of acid and the intensity of the color is measured at a wavelength of 450nm \pm 2nm.

Human Dengue Virus IgG antibody ELISA Kit ARG80538

MATERIALS PROVIDED & STORAGE INFORMATION

Store the unopened kit at 2-8 °C. Use the kit before expiration date.

Component	Quantity	Storage information
Antigen-coated microplate	8 X 12 strips	4°C. Unused strips should be sealed tightly in the air-tight pouch.
Calibrator A (Negative Control)	2 ml (Ready-to-use)	4°C
Calibrator B (Cut-off control)	3 ml (Ready-to-use)	4°C
Calibrator C (Weak Positive Control)	2 ml (Ready-to-use)	4°C
HRP-conjugated antibody	20 ml (Ready-to-use)	4°C
Sample Diluent	100 ml (Ready-to-use)	4°C
20X Wash buffer	50 ml	4°C
TMB substrate	15 ml (Ready-to-use)	4°C (Protect from light)
STOP solution	15 ml (Ready-to-use)	4°C
Plate sealer	1 strip	RT

MATERIALS REQUIRED BUT NOT PROVIDED

- Microplate reader capable of measuring absorbance at 450nm (Optional: 620 nm as reference wavelength)
- Pipettes and pipette tips
- Deionized or distilled water
- 37°C oven or incubator
- Automated microplate washer (optional)

TECHNICAL HINTS AND PRECAUTIONS

- Wear protective gloves, clothing, eye, and face protection especially while handling blood or body fluid samples.
- Store the kit at 4°C at all times.
- Unused strips should be resealed in the aluminium foil along with the desiccant supplied and stored at 2-8 °C.
- If crystals are observed in the 20X Wash buffer, warm to RT or 37°C until the crystals are completely dissolved. Mix well before dilution.
- The TMB Color developing agent should be colorless (or could have a slight blue tinge) and transparent before using.
- Ensure complete reconstitution and dilution of reagents prior to use.
- All reagents should be mixed by gentle inversion or swirling prior to use. Do not induce foaming.
- Before using the kit, spin tubes and bring down all components to the bottom of tubes.
- All materials should be equilibrated to room temperature (RT; 20-25°C) before use.
- It is highly recommended that the standards, samples and controls be assayed in duplicates.
- Perform all assay steps in the order given and without any delays.
- Change pipette tips between the addition of different reagent or samples.

SAMPLE COLLECTION & STORAGE INFORMATION

The sample collection and storage conditions listed below are intended as general guidelines. Sample stability has not been evaluated.

Serum- Use a serum separator tube (SST) and allow samples to clot for 30 minutes before centrifugation for 15 minutes at 1000 x g. Collect serum and assay immediately or aliquot and store samples at -20 or -70°C. Avoid repeated freeze-thaw cycles.

Plasma - Collect plasma using citrate and heparin as an anticoagulant. Centrifuge for 15 minutes at 1000 x g within 30 minutes of collection. Assay immediately or aliquot and store samples at -20 or -70°C. Avoid repeated freeze-thaw cycles.

Note:

If samples are frozen, mix thawed samples well before testing. Avoid repeated freezing and thawing. Heat inactivation of samples is not recommended.

REAGENT PREPARATION

- **1X Wash buffer:** Dilute **20X** Wash buffer into **distilled water** to yield 1X Wash buffer. (e.g. 10 ml of 20X Wash buffer +190 ml of distilled water). Mix thoroughly by Use a magnetic stirrer. The diluted 1X wash buffer is stable for 5 days at room temperature (20-25 °C).
- **Patient sample:** Dilute patient sample **1:101** with **Sample diluent buffer** before assay, mix well. (e.g. 5 µl of serum + 500 µl of sample diluent buffer)

Note: *The controls are ready-to-use and need not further dilution.*

Human Dengue Virus IgG antibody ELISA Kit ARG80538

ASSAY PROCEDURE

All materials should be equilibrated to room temperature (RT, 20-25 °C) before use. Standards, samples and controls should be assayed in duplicates.

1. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal it.
2. Add **100 µl** of **controls, diluted samples (1:101)** into wells. Leave well A1 for the Substrate Blank. Cover the wells and incubate for **1h at 37°C**.
3. Aspirate each well and wash, repeating the process 2 times for a **total 3 washes** (for automatic systems wash the wells for a total 5 washes). Wash by filling each well with **1× Wash Buffer (350 µl)** using a squirt bottle, manifold dispenser, or autowasher. Avoid overflows from the reaction wells. Keep the wash buffer in the wells for > 5 sec before removal. Complete removal of liquid at each is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating, decanting or blotting against clean paper towels.
4. Add **100 µl** of **HRP-conjugated antibody** into each well (except for the Substrate Blank well A1). Cover wells and incubate for **30 minutes at RT**.
5. Aspirate each well and **wash as step 3**.
6. Add **100 µl** of **TMB Substrate Reagent** to each well. Incubate for **15 minutes at room temperature in dark**. A blue color occurs due to an enzymatic reaction.
7. Add **100 µl** of **Stop Solution** to each well. The color of the solution should change from blue to yellow.
8. Read the OD with a microplate reader at **450 nm** (and reference filter **620 nm**) immediately. It is recommended read the absorbance within 30 minutes after adding the stop solution.

CALCULATION OF RESULTS

1. In order for an assay to be considered valid, the following criteria must be met:

Substrate blank: Absorbance value **<0.1**

Negative control: Absorbance value **<0.2 and <cut-off**

Cut-off control: Absorbance value **0.15-1.3**

Positive control: Absorbance value **>cut-off**

If these criteria are not met, the test is not valid and must be repeated.

2. Calculation of Results

The Cut-off is the mean absorbance value of the Cut-off Control determinations.

Example: Absorbance value of Cut-off Control well 1 = 0.5

absorbance value Cut-off control well 2 = 0.52

Control mean absorbance = Cut-off = $(0.5+0.52)/2 = 0.51$

3. Results in Units [U]

Units [U] = [Sample (mean) absorbance value x 10] / Cut-off

Example: $(1.2 \times 10) / 0.51 = 23.5$ U (Units)

Note: $\text{Cut-off} = (\text{Cut-off} \times 10) / \text{Cut-off} = 10$ U

Human Dengue Virus IgG antibody ELISA Kit ARG80538

4. Interpretation of results:

- The samples are considered positive if the absorbance value is higher than 10% over the cut-off.
- Samples with absorbance value of 10% above or below cut-off should be considered in the grey zone.

It is recommended to repeat test again 2-4 weeks later with fresh sample. If the results in the second test are again in the grey zone, the sample has to be considered negative.

- Samples are considered negative if the absorbance value is lower than 10% below the cut-off.

Summary:

	Unit	Note
Cut-off	10 U	-
Positive	> 11 U	Antibodies to Dengue Virus were detected.
Equivocal	9 – 11 U	Antibodies to Dengue Virus could not be detected clearly.
Negative	< 9 U	Antibodies to Dengue Virus could not be detected

Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history, symptomatology as well as serological data.

In immunocompromised patients and newborns serological data only have restricted value.

QUALITY ASSURANCE

Intra-assay and Inter-assay precision

The CV value of intra-assay precision is 3.09 % and inter-assay precision is 8.73%.

Specificity

The specificity is defined as the probability of the assay of scoring negative in the absence of the specific analyte. It is 95.87% (95% confidence interval: 90.62%- 98.64%).

Sensitivity

The sensitivity is defined as the probability of the assay of scoring positive in the presence of the specific analyte. It is 100.0% (95% confidence interval: 93.62%- 100.0%).

Cross Reactivity

This kit is able to detect virus serotypes of DENV-1, DENV-2, DENV-3, and DENV-4.

Cross reactivity with other flaviviruses should be taken into account for result interpretation. In addition, in endemic areas, double infection as well as past infection with other arbo- or flaviviruses should be considered.

Interferences

Interferences with hemolytic, lipemic or icteric samples are not observed up to a concentration of 10 mg/ml hemoglobin, 5 mg/ml triglycerides and 0.5 mg/ml bilirubin.